Free Trial
→ Reagan’s former tech advisor sharing bombshell announcement (From Banyan Hill Publishing) (Ad)tc pixel Free BCT Stock Alerts

BriaCell Therapeutics (BCT) Competitors

BriaCell Therapeutics logo
C$11.05 -0.22 (-1.95%)
As of 09/12/2025 03:30 PM Eastern
Compare

BCT vs. PDP, SVA, COV, EMH, PMN, DMT, IBT, MBX, RVX, and GSD

Should you be buying BriaCell Therapeutics stock or one of its competitors? The main competitors of BriaCell Therapeutics include Pediapharm (PDP), Sernova (SVA), Covalon Technologies (COV), Emerald Health Therapeutics (EMH), ProMIS Neurosciences (PMN), Small Pharma (DMT), IBEX Technologies (IBT), Microbix Biosystems (MBX), Resverlogix (RVX), and Devonian Health Group (GSD). These companies are all part of the "biotechnology" industry.

BriaCell Therapeutics vs. Its Competitors

Pediapharm (CVE:PDP) and BriaCell Therapeutics (TSE:BCT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends, media sentiment and valuation.

BriaCell Therapeutics has lower revenue, but higher earnings than Pediapharm. Pediapharm is trading at a lower price-to-earnings ratio than BriaCell Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PediapharmC$11.16M5.95-C$16.15M-C$0.07-4.11
BriaCell TherapeuticsN/AN/A-C$2.37M-C$76.90-0.14

In the previous week, Pediapharm's average media sentiment score of 0.00 equaled BriaCell Therapeutics'average media sentiment score.

Company Overall Sentiment
Pediapharm Neutral
BriaCell Therapeutics Neutral

0.0% of BriaCell Therapeutics shares are held by institutional investors. 9.3% of BriaCell Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

BriaCell Therapeutics' return on equity of 536.29% beat Pediapharm's return on equity.

Company Net Margins Return on Equity Return on Assets
PediapharmN/A N/A N/A
BriaCell Therapeutics N/A 536.29%-122.71%

Summary

BriaCell Therapeutics beats Pediapharm on 5 of the 8 factors compared between the two stocks.

Get BriaCell Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for BCT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BCT vs. The Competition

Export to Excel
MetricBriaCell TherapeuticsBiotechnology IndustryMedical SectorTSE Exchange
Market CapC$19.39MC$236.97MC$5.87BC$9.40B
Dividend Yield13.70%3.78%5.68%6.51%
P/E Ratio-0.1441.0874.5225.78
Price / SalesN/A5,000.68516.439.40
Price / CashN/A13.1937.5683.29
Price / Book53.65103.7512.165.54
Net Income-C$2.37M-C$90.99MC$3.28BC$301.20M
7 Day Performance2.79%2.70%0.78%1.40%
1 Month Performance11.62%21.05%4.87%7.72%
1 Year Performance43.51%530.95%60.72%36.76%

BriaCell Therapeutics Competitors List

Export to Excel
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BCT
BriaCell Therapeutics
N/AC$11.05
-2.0%		N/A+31.5%C$19.39MN/A-0.1416Gap Down
PDP
Pediapharm
N/AC$0.30
+1.7%		N/A+0.0%C$66.36MC$11.16M-4.11N/A
SVA
Sernova
N/AC$0.20
+11.4%		C$2.00
+925.6%		-33.3%C$64.06MN/A-2.791,959Gap Down
COV
Covalon Technologies
N/AC$2.28
flat		N/A-25.4%C$62.51MC$32.99M25.33N/A
EMH
Emerald Health Therapeutics
N/AC$0.26
-3.8%		N/A+0.0%C$52.28MC$13.02M-0.37161
PMN
ProMIS Neurosciences
N/AN/AN/AN/AC$51.48MC$7.56K-1.786Gap Up
High Trading Volume
DMT
Small Pharma
N/AC$0.15
-6.3%		N/A+0.0%C$50.37M-C$1.16K-2.1413Gap Down
High Trading Volume
IBT
IBEX Technologies
N/AC$1.44
flat		N/A+0.0%C$35.54MC$5.77M11.52N/A
MBX
Microbix Biosystems
N/AC$0.24
+4.4%		N/A-31.9%C$32.96MC$21.13M-117.50N/A
RVX
Resverlogix
N/AC$0.10
flat		N/A+33.3%C$28.64MN/A-2.5019High Trading Volume
GSD
Devonian Health Group
N/AC$0.18
+2.9%		N/A+6.3%C$25.94MC$30.97M-6.256Gap Up

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (TSE:BCT) was last updated on 9/13/2025 by MarketBeat.com Staff
From Our Partners
Why Trump’s “Smart Dollar” could rewrite the rules
MUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...
Stansberry Research | Sponsoredtc pixel
Trump's Law S.1582: $21T Dollar Revolution Coming
Do you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...
Brownstone Research | Sponsoredtc pixel
Retire Comfortably with These New Monthly Income ETFs?
Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...
Investors Alley | Sponsoredtc pixel
“Fed Proof” Your Bank Account with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank ac...
Weiss Ratings | Sponsoredtc pixel
October 16 Changes the Microchip Game — and Investing
While everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...
Banyan Hill Publishing | Sponsoredtc pixel
INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.
Traders Agency | Sponsoredtc pixel
Forget Tesla — This Tiny AI Stock Is Musk’s Real Play
While Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...
Behind the Markets | Sponsoredtc pixel
Nvidia Times 1,000,000
Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...
Paradigm Press | Sponsoredtc pixel